Zentalis Pharmaceuticals (ZNTL) has just posted its FY 2025 first half results with total revenue at US$0 million, basic EPS at a loss of US$1.05, and net income excluding extraordinary items at a loss of US$75.2 million. This puts the focus firmly on expense control and cash burn. Over the recent periods, the company has seen revenue move from US$40.6 million in the first half of 2024 to US$26.9 million in the second half of 2024, before dropping to zero in the latest half. Half year basic EPS losses have remained in a tight band around the US$1.05 to US$1.23 range, keeping margins under pressure and placing the onus on future revenue drivers rather than current profitability.

See our full analysis for Zentalis Pharmaceuticals.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the prevailing stories about Zentalis, and where the hard data backs or questions those narratives.

TTM losses at US$162.8 million frame Zentalis as a cash-burning developer

• Over the trailing twelve months, Zentalis recorded total revenue of US$26.9 million and a net loss excluding extraordinary items of US$162.8 million, while basic EPS over that period was a loss of US$2.28.
• Critics highlight that losses have grown at about 4.4% per year over the past five years and see the TTM net loss of US$162.8 million as reinforcing a bearish view that the business is still firmly in funding and development mode rather than moving toward self-sustaining operations.
  • This bearish angle is supported by the FY 2025 first half loss of US$75.2 million, which sits close to the FY 2024 half year losses of US$78.2 million and US$87.6 million, pointing to consistently heavy spending.
  • With basic EPS losses per half in a narrow range between about US$1.05 and US$1.23 and no sign of a move toward profitability in the TTM data, bears argue that near term results are more about how long this level of cash burn can be maintained than about earnings progress.

Some investors will want to see how this loss profile compares to other clinical stage names and what assumptions sit behind the long term profitability story before making any calls on the share.

Zero FY 2025 first half revenue versus low 5.1x P/S multiple

• The first half of FY 2025 came in with total revenue of US$0 against the backdrop of a P/S ratio of 5.1x, which is below both the peer average of 18.8x and the US Biotech industry average of 10.8x based on the trailing revenue base of US$26.9 million.
• What stands out for a bullish angle is the tension between this lower P/S multiple and the fact that recent half year revenue has slid from US$40.6 million in early 2024 to US$26.9 million in late 2024 and then to zero in the latest half. This means anyone leaning on the lower multiple needs to square it with the lack of current top line.
  • Bulls who focus on the valuation gap may point to the P/S discount and the presence of revenue in the prior year, but the current period figure of US$0 revenue means the multiple is anchored to past revenue rather than any visible ongoing sales base.
  • Those same bulls need to factor in that revenue is expected to be zero next year according to the provided data, so the case built on today’s P/S level is being made while the operating line is still revenue free.

US$2.10 share price versus US$47.04 DCF fair value

• The current share price of US$2.10 is well below the stated DCF fair value of US$47.04, and this sits alongside trailing losses of US$162.8 million and a view that the company is not expected to be profitable over the next three years.
• Supporters of a bullish narrative might see this gap between DCF fair value and market price as an opportunity. Yet the same dataset flags high share price volatility over the past three months and significant insider selling in the past quarter, which together raise questions about how quickly, if at all, the market will respond to that DCF figure.
  • The DCF fair value implies a very large multiple of the current US$2.10 share price, while the ongoing net losses and lack of forecast profitability give bears concrete reasons to question whether that valuation will be reflected in the market.
  • High recent volatility and insider selling mean that even with a low P/S of 5.1x and a big DCF gap on paper, investors are being asked to weigh this against clear risk markers in the recent trading and ownership data.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Zentalis Pharmaceuticals's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With sentiment clearly split between the risks around ongoing losses and the potential rewards implied by valuation and narratives, now is a good time to check the numbers yourself and decide how they stack up for your goals, starting with these 2 key rewards and 3 important warning signs.

Explore Alternatives

Zentalis currently has zero revenue, recurring losses of more than US$75 million per half year, and no forecast profitability. This puts cash burn and risk front and center.

If you want ideas with clearer resilience and less balance sheet stress, start comparing names in the 67 resilient stocks with low risk scores to see how they stack up against this profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.